Pharmaceutical nanotechnology最新文献

Solid lipid nanoparticles (SLNs) are gaining significant attention in the pharmaceutical industry due to their biocompatibility and biodegradability, making them a popular functional nanocarrier. SLNs are a popular nanocarrier due to their ability to bypass the spleen and liver, offer high drug stability, and improve bioavailability, sterilization, immobilization, targeted drug release, and biocompatible ingredients. This article discusses various SLN preparation techniques, including high shear homogenization, hot homogenization, cold homogenization, microemulsion-based, solvent evaporation, solvent emulsification-evaporation, supercritical fluid-based, spray drying, double emulsion, and precipitation techniques, focusing on methodological aspects. This review discusses the physicochemical behavior of SLNs, including drug loading, release, particle size, stability, cytotoxicity, and cellular uptake, and their major biomedical applications.

Liquid crystalline lipid nanoparticles (LCNPs) represent a type of membrane-based nano-carriers formed through the self-assembly of lyotropic lipids. These lipids, such as unsaturated monoglycerides, phospholipids, and co-lipids, create liquid crystals or vesicles with an aqueous core enclosed by a natural or synthetic phospholipid bilayer upon exposure to an aqueous medium. Liquid crystalline lipid nanoparticles (LCNPs), akin to liposomes, have garnered significant attention as nanocarriers suitable for a diverse range of hydrophobic and hydrophilic molecules. Their notable structural advantage lies in a mono-channel network organization and the presence of multiple compartments, resulting in heightened encapsulation efficiency for various substances. Cubosomes, spongosomes, hexosomes, and multicompartment nanoparticles are examples of lipid nanocarriers with interior liquid crystalline structures that have recently gained a lot of interest as effective drug delivery systems. Additionally, LCNPs facilitate the sustained release of encapsulated compounds, including therapeutic macromolecules. This review delves into the structure of liquid crystalline lipid nanoparticles, explores preparation techniques, and outlines their applications in the context of skin cancer.

The review aims to assess the potential of niosomes-nonionic surfactant-based vesicular systems-as carriers for topical and transdermal drug delivery. Niosomes enable targeted and controlled drug release while minimizing systemic toxicity. The investigation centers on their structure, stability, and capacity to entrap both hydrophilic and lipophilic drugs, as well as their use in managing various dermatological and systemic disorders. Recent studies have examined the formulation of niosomes, particularly highlighting the roles of nonionic surfactants and cholesterol in enhancing the stability and entrapment efficiency of these vesicles. Research on permeability enhancers has been reviewed for their ability to work together to improve drug transport and bioavailability. It also provides a detailed discussion on the use of niosomes in treating various dermatological conditions, as well as their applications in systemic diseases, with a particular focus on co-delivery systems in cancer therapies. Niosomes exhibit efficacy in drug delivery by providing an increase in penetration through the stratum corneum, targeting hydrophilic and lipophilic drugs for dermatological and systemic applications. The Development of niosomal therapy has expanded into immunization, antiinflammatory treatments, and the control of pigmentation. Permeability enhancers further increase their efficacy, bioavailability, and tissue localization. Anticancer treatment using niosomes for codelivery of agents demonstrates synergistic effects with reduced side effects. Niosomes have tremendous potential in advancing topical and transdermal drug delivery, offering controlled, targeted release and improved patient outcomes. With optimized fabrication and comprehensive toxicity evaluation, niosomes can potentially revolutionize topical therapies, making them safer, more effective, and patient-friendly for a range of next-generation treatment options across dermatology and beyond.

The drug was initially administrated relying on pills, eye drops, ointments, and intravenous solutions. In the last decades, several novel technologies have emerged to overcome significant challenges including poor solubility, drug aggregation, low bioavailability, limited biodistribution, poor absorption in the body, lack of selectivity, or to minimize the adverse effects of therapeutic drugs. Drug delivery systems (DDS) can be designed to the technologies that carry drugs into or throughout the body of humans or animals to enhance therapeutic efficacy. DDS can also be considered for in vivo delivery, particularly for their use in peptide and protein therapeutics. Continued research may show the trends and perspectives of how drugs are delivered. In addition, this article includes comprehensive information regarding the trends and perspectives in DDS technologies.

Introduction/ Background: This study aimed to introduce a gel (NEG) formulation containing betulin-loaded nanoemulsions for topical psoriasis treatment.

Materials and methods: The prepared nanoemulsions were optimized for smaller particle size and higher drug content using a response surface methodology that exhibited uniform distribution and high drug loading (21.17±3.55%).

Results: The gel demonstrated skin-compatible pH and good spreadability. The developed gel showed slower release compared to nanoemulsion. In vivo pharmacokinetics demonstrated elevated AUC (55835.1 μg/cm2.h) and extended Tmax (720 min) for the gel than NE, indicating extended skin retention. Improved skin hydration (35%) and lipid content (28%) were observed, along with significant reductions in PASI scores and cytokine levels.

Discussion: Provided with enhanced skin retention, improved hydration, and lipid content, along with significant therapeutic efficacy in psoriasis treatment, betulin-loaded nanoemulsion gel demonstrated prolonged drug release and notably reduced PASI scores and cytokine levels, highlighting its effectiveness against psoriasis.

Conclusion: This highlights the promising potential of NEG for topical psoriasis management.

Cancer continues to pose a formidable challenge in global health due to its incidence and increasing resistance to conventional therapies. A key factor driving this resistance is tumor hypoxia, characterized by reduced oxygen levels within cancer cells. This hypoxic environment triggers a variety of adaptive mechanisms, significantly compromising the efficacy of cancer treatments. Notably, hypoxia promotes metastasis and reshapes the tumor microenvironment (TME), thereby aggravating treatment resistance. Central to this process are hypoxia-inducible factors (HIFs), which mediate cellular adaptations such as metabolic shifts and enhanced survival pathways. These adaptations render therapies like chemotherapy, radiotherapy, and photodynamic therapy (PDT) less effective. Additionally, hypoxia-induced vascular irregularities further impede drug delivery, amplifying the therapeutic challenge. This review provides a comprehensive examination of the roles of hypoxia in cancer, its contributions to drug resistance, and its interplay with apoptosis and autophagy. By evaluating novel mechanistic and translational approaches to target hypoxia, this study highlights the potential to improve therapeutic outcomes and offers insights into overcoming treatment resistance in cancer.

Rheumatoid Arthritis (RA) is a chronic autoimmune disorder characterized by inflammation in the joints, leading to pain, swelling, stiffness, and eventual joint damage. This condition occurs when the body's immune system mistakenly attacks the synovium, the lining of the membranes surrounding the joints. Treatment focuses on reducing inflammation, alleviating pain, and preventing joint damage through a combination of medications, physical therapy, and lifestyle modifications. Recently, biological therapies have been introduced, including Tumour Necrosis Factor (TNF) blockers (such as etanercept, infliximab, and adalimumab), IL-6 inhibitors (tocilizumab), and interleukin- 1 inhibitors (anakinra). These treatments can lead to various side effects. The use of herbalbased treatments, such as secondary metabolites, has gained popularity due to their better tolerability, safety, and effectiveness compared to conventional therapies. However, there are also some limitations, like poor bioavailability and permeability and lower stability; to overcome these issues, Novel Drug Delivery Systems (NDDS) have been introduced as better treatment options in recent years. Polymer science advancements and nanotechnology applications have opened new avenues for RA treatment, emphasizing the development of smart drug delivery systems. These systems aim to improve therapeutic outcomes while minimizing adverse effects. Additionally, newly synthesized biocompatible drug delivery systems, combined with anti-inflammatory drugs composed of secondary metabolites, offer potential solutions for RA.

Periodontitis (PD) is a pathological condition that results in chronic swelling in the tissue around a tooth, which results in advanced periodontal structural injury to the encircling soft and hard tissues with eventual exfoliation and movement of teeth. It affects around 60% of the world's population, indicating a relatively high prevalence. Therefore, the discovery of efficient therapeutic interventions for dental disorders is a primary goal of the health sciences, and periodontitis is a significant public health problem. Currently, perioceutics plays a revolutionary role in periodontal therapy with the introduction of both systemic and local route administration of therapeutic drugs as supportive therapy to SRP (Scaling and Root Planning). The key to effective periodontal treatment is the selection of the proper antibacterial agent and the local route of medication delivery. The items mentioned, including irrigation systems, gels, fibers, films, thin strips, microvesicles, zero-dimensional nanomaterial, and moderate-dose biocide agents, reflect the innovative site-specific drug delivery available in the sector, resulting in the fulfillment of antimicrobial substances to sites of periodontal disease with low to non-existent negative impacts on other bodily systems. The current report seeks to present the most recent technologies in local biomaterial-based delivery with different properties that play a significant role in gum disease so that the practitioners are able to select appropriate bioactive agents for LDDS that are custom-tailored for a given clinical condition, identify present obstacles, and determine the future research opportunities.

Alzheimer's disease (AD) is an irreversible brain disorder that led to memory loss and disrupts daily life. Earlier strategies to treat AD such as acetylcholinesterase inhibitor (AChEI) drugs are not showing effectiveness due to the inability to cross the blood-brain barrier. Moreover, traditional AChEI provides limited efficacy in terms of bioavailability and solubility for treating AD treatment. Many of the current drugs such as donepezil taken to treat the disease exhibited harmful side effects. Hence, researchers are keen to find the alternative effective therapeutic agents for treating AD. This review summarizes the recent advancement in nanotechnology-based drug delivery systems of herbal drugs such as Curcumin, Ginkgo biloba, Salvia officinalis, etc for the prevention and cure of AD. Herbal drugs proved useful in treating neuronal disorders such as AD but exhibited some limitations like low bioavailability via oral drug delivery. Such limitations were overcome by tagging these drugs by nanoparticles which enables them to cross the blood-brain barrier and offer the delivery of greater concentration of herbal drugs to the brain. Inorganic nanoparticle-based drugdelivery systems such as gold nanoparticles and magnetic nanoparticles, organic nanoparticulate systems like polymeric micelles and dendrimers, and solid polymeric nanoparticles were some of the effective methods that have earlier shown potential for enhancing the delivery of herbal drugs to the brain. Long-term repeated injection of drugs loaded on nanomaterials can lead to the accumulation of nanomaterials in the body without timely and effective degradation which can cause serious issues to the brain. Hence, nanotechnology-based strategies should involve the formulation of nontoxic nanoparticles in such a way that they can significantly transport the drugs across the BBB followed by effective degradation of nanoparticles.

Background: Tapentadol hydrochloride is a potent analgesic commonly used to manage moderate to severe pain. Rapidly dissolving tablets of Tapentadol offer a significant advantage in enhancing patient compliance by providing quick pain relief. The development of fast-dissolving tablets (FDTs) requires careful consideration of formulation parameters to achieve optimal disintegration and dissolution profiles. In this study, the aim was to fabricate Tapentadol FDTs by selecting suitable super disintegrating agents such as croscarmellose sodium and crospovidone, which serve as two independent variables. The direct compression method was employed to formulate nine different Tapentadol hydrochloride formulations (TH1 to TH9).

Materials and methods: The study utilized Design-Expert® software version 13.0 and the Response Surface Methodology (RSM) for the optimization of Tapentadol FDTs. The formulations were prepared using the direct compression method with varying concentrations of the super disintegrants, croscarmellose sodium, and crospovidone. The primary response variables considered in this optimization study included disintegration time (Y1), percentage drug release at 15 minutes (Q15, Y2), and percentage drug release at 30 minutes (Q30, Y3). All pre-compressional and postcompressional parameters were evaluated for each formulation, along with in vitro dissolution studies. Furthermore, DD Solver, a statistical tool, was employed to determine the kinetics of drug release and the release order mechanism based on regression coefficient value (r²), Akaike Information Criterion (AIC), and Model Selection Criteria (MSC).

Results: The evaluation studies indicated that the TH5 formulation exhibited the most rapid disintegration time and the highest drug release percentage within the specified time frame. The super disintegrants used demonstrated a significant impact on the response variables, notably enhancing the solubility and dissolution rate of Tapentadol hydrochloride. Based on the exponent release (n) value, the study concluded that the TH5 formulation followed a first-order release kinetics and Fickian diffusion mechanism for drug release. Stability studies were performed following the International Council for Harmonization (ICH) guidelines to assess the shelf-life of the optimized formulation. The ANOVA data revealed that the p-value was greater than 0.05, indicating no significant differences during the storage period. Additionally, a similarity factor (f2) analysis was conducted to compare the optimized formulation with the marketed formulation (Tydol 100 mg).

Discussion: The findings highlight the crucial role of super disintegrants in fast-dissolving tablet formulation, significantly impacting disintegration time and dissolution profile. The TH5 formulation excelled in rapid disintegration and drug release, optimized using RSM and Design-Expert software,